Role of abciximab in the treatment of coronary artery disease (Q28200177)

Expert Opinion on Biological Therapy

Europe PubMed Central

title

Role of abciximab in the treatment of coronary artery disease (English)

0 references

main subject

coronary artery disease

1 reference

H Mesquita Gabriel

1

0 references

Eduardo Infante Oliveira

series ordinal

2

0 references

language of work or name

English

0 references

publication date

September 2006

0 references

published in

0 references

volume

6

0 references

issue

9

0 references

page(s)

935-42

0 references

cites work

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Abciximab readministration: results of the ReoPro Readministration Registry

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

A population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-ST elevation myocardial infarction

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.6.9.935

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Final results of the ReoPro readministration registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935

Cilostazol: a review of its use in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.935